Well, according to the ann, the CDH17 trials are being fast-tracked in the sense that they are staged. Stage 1 is dose escalation and Stage 2 expanded recruitment at the optimal dose for each of three different trials (or cancer types). That is smart trial design. Instead of a doing a single basket trial and hoping for one-size dose fits all approach, its honing in on getting maximum clinical activity in what is traditionally just a safety trial. In a way, it truncates the process and potentially ensures the next (possible) trials for CDH17 will be registrational trials.
This shows what the CHM management are considering as an achievable timeline for each of our programs within the year:-
So, we have lots of clinical milestones, data and pre-clinical newsflow to come.... and we are already into the 7th of the year. The funding issue is likely to be an interesting one given the pipeline and the newsflow for the rest of 2024.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)